Biologics in Chronic Rhinosinusitis: Current and Emerging.

Authors :: Boyd JT
Khanwalkar AR
Source :: Immunology and allergy clinics of North America [Immunol Allergy Clin North Am] 2024 Nov; Vol. 44 (4), pp. 657-671. Date of Electronic Publication: 2024 Aug 17.
Publication Year :: 2024
Abstract: Chronic rhinosinusitis (CRS) is categorized phenotypically into CRS with and without nasal polyps (CRSwNP, CRSsNP). Endotyping categorizes the disease based on immune cell activity and inflammatory mechanisms into Type 1, Type 2, and Type 3. The Type 2 endotype is the most researched and associated with asthma, atopic disease, and severe CRSwNP. For patients with poorly controlled CRSwNP, there are 3 approved biologic treatments: omalizumab, dupilumab, and mepolizumab. Many other biologics are being tested in Type 2, non-Type 2, and mixed endotypes in CRSwNP and CRSsNP. These studies will play a significant role in shaping the future of CRS management.<br />Competing Interests: Disclosure The authors have no relevant disclosures.<br /> (Copyright © 2024 Elsevier Inc. All rights reserved.)